Smith+Nephew, the FTSE 100 medical technology group, announced the commercial launch of its LYNX COBLATION Laryngeal Wand, a device designed for ear, nose and throat (ENT) surgeons performing airway procedures.
The wand supports procedures ranging from the supraglottis to the trachea, combining fine dissection and mass debulking in a single tool designed to operate at low temperatures with reduced risk of airway fire compared with electrocautery or CO2 laser methods.
The product uses Smith+Nephew's patented COBLATION ENT technology, a tissue-removal method with more than 20 years of clinical use and over 240 peer-reviewed publications behind it.
Key design features include self-clearing capabilities to reduce clogging during use, a long working length enabling 360-degree radial incisions, and a malleable shaft that adapts to patient anatomy.
Dr Priya Krishna, professor at Loma Linda University Health System's Department of Otolaryngology-Head and Neck Surgery, was among the first to use the device.
"The LYNX Wand is very efficient in its completeness of tissue removal, and the extended length makes it versatile," she said.
Meghan Mavity, senior vice president and general manager of ENT at Smith+Nephew, said the company designed the wand specifically in response to surgeon demand for a single, streamlined airway solution.
The launch adds to Smith+Nephew's Sports Medicine & ENT business unit, one of three global divisions alongside Orthopaedics and Advanced Wound Management, within a group that generated $6.2 billion in sales in 2025.
